News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evotec AG (EVTG.F): New Hormone to Treat Diabetes Published in "Cell"


4/26/2013 11:06:09 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAMBURG, Germany, April 26, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced an auspicious step in research from Harvard University. The findings are published in a scientific article by Prof. Doug Melton, University professor at Harvard University and Howard Hughes Medical Institute (HHMI) investigator and his post doc Peng Yi in the journal Cell. Doug Melton is the academic key collaborator of CureBeta, a strategic alliance between Harvard University, Evotec and Janssen Pharmaceuticals in the field of beta cell regeneration.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
Evotec AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES